COMPUESTOS ANTAGONISTAS DE PCSK9
Se divulgan compuestos de Fórmula I, o una sal de los mismos: donde A, B, D, X, R1, R2 y R8 son como se definen en el presente documento, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SOBHANA BABU BOGA HUBERT B. JOSIEN ABBAS M. WALJI ELISABETTA BIANCHI DANILA BRANCA HAROLD B. WOOD FA-XIANG DING SOOKHEE NICOLE HA CHENGWEI WU YUSHENG XIONG JIAN LIU ANGELA DAWN KEREKES THOMAS JOSEPH TUCKER ANIKUMAR G. NAIR LING TONG |
| description | Se divulgan compuestos de Fórmula I, o una sal de los mismos: donde A, B, D, X, R1, R2 y R8 son como se definen en el presente documento, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales, y métodos para tratar enfermedades cardiovasculares y afecciones relacionadas con la actividad de PCSK9, ej., aterosclerosis, hipercolesterolemia, cardiopatía coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NI202000101A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NI202000101A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NI202000101A3</originalsourceid><addsrcrecordid>eNrjZFBw9vcNCHUNDvEPVnD0C3F09_fzDA5xDFZwcVUIcA72tuRhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfF-nkYGRgYGBoYGho7GxKgBAP5dIdA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPUESTOS ANTAGONISTAS DE PCSK9</title><source>esp@cenet</source><creator>SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; HAROLD B. WOOD ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; ANIKUMAR G. NAIR ; LING TONG</creator><creatorcontrib>SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; HAROLD B. WOOD ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; ANIKUMAR G. NAIR ; LING TONG</creatorcontrib><description>Se divulgan compuestos de Fórmula I, o una sal de los mismos: donde A, B, D, X, R1, R2 y R8 son como se definen en el presente documento, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales, y métodos para tratar enfermedades cardiovasculares y afecciones relacionadas con la actividad de PCSK9, ej., aterosclerosis, hipercolesterolemia, cardiopatía coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</description><language>spa</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210528&DB=EPODOC&CC=NI&NR=202000101A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210528&DB=EPODOC&CC=NI&NR=202000101A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SOBHANA BABU BOGA</creatorcontrib><creatorcontrib>HUBERT B. JOSIEN</creatorcontrib><creatorcontrib>ABBAS M. WALJI</creatorcontrib><creatorcontrib>ELISABETTA BIANCHI</creatorcontrib><creatorcontrib>DANILA BRANCA</creatorcontrib><creatorcontrib>HAROLD B. WOOD</creatorcontrib><creatorcontrib>FA-XIANG DING</creatorcontrib><creatorcontrib>SOOKHEE NICOLE HA</creatorcontrib><creatorcontrib>CHENGWEI WU</creatorcontrib><creatorcontrib>YUSHENG XIONG</creatorcontrib><creatorcontrib>JIAN LIU</creatorcontrib><creatorcontrib>ANGELA DAWN KEREKES</creatorcontrib><creatorcontrib>THOMAS JOSEPH TUCKER</creatorcontrib><creatorcontrib>ANIKUMAR G. NAIR</creatorcontrib><creatorcontrib>LING TONG</creatorcontrib><title>COMPUESTOS ANTAGONISTAS DE PCSK9</title><description>Se divulgan compuestos de Fórmula I, o una sal de los mismos: donde A, B, D, X, R1, R2 y R8 son como se definen en el presente documento, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales, y métodos para tratar enfermedades cardiovasculares y afecciones relacionadas con la actividad de PCSK9, ej., aterosclerosis, hipercolesterolemia, cardiopatía coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFBw9vcNCHUNDvEPVnD0C3F09_fzDA5xDFZwcVUIcA72tuRhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfF-nkYGRgYGBoYGho7GxKgBAP5dIdA</recordid><startdate>20210528</startdate><enddate>20210528</enddate><creator>SOBHANA BABU BOGA</creator><creator>HUBERT B. JOSIEN</creator><creator>ABBAS M. WALJI</creator><creator>ELISABETTA BIANCHI</creator><creator>DANILA BRANCA</creator><creator>HAROLD B. WOOD</creator><creator>FA-XIANG DING</creator><creator>SOOKHEE NICOLE HA</creator><creator>CHENGWEI WU</creator><creator>YUSHENG XIONG</creator><creator>JIAN LIU</creator><creator>ANGELA DAWN KEREKES</creator><creator>THOMAS JOSEPH TUCKER</creator><creator>ANIKUMAR G. NAIR</creator><creator>LING TONG</creator><scope>EVB</scope></search><sort><creationdate>20210528</creationdate><title>COMPUESTOS ANTAGONISTAS DE PCSK9</title><author>SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; HAROLD B. WOOD ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; ANIKUMAR G. NAIR ; LING TONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NI202000101A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>SOBHANA BABU BOGA</creatorcontrib><creatorcontrib>HUBERT B. JOSIEN</creatorcontrib><creatorcontrib>ABBAS M. WALJI</creatorcontrib><creatorcontrib>ELISABETTA BIANCHI</creatorcontrib><creatorcontrib>DANILA BRANCA</creatorcontrib><creatorcontrib>HAROLD B. WOOD</creatorcontrib><creatorcontrib>FA-XIANG DING</creatorcontrib><creatorcontrib>SOOKHEE NICOLE HA</creatorcontrib><creatorcontrib>CHENGWEI WU</creatorcontrib><creatorcontrib>YUSHENG XIONG</creatorcontrib><creatorcontrib>JIAN LIU</creatorcontrib><creatorcontrib>ANGELA DAWN KEREKES</creatorcontrib><creatorcontrib>THOMAS JOSEPH TUCKER</creatorcontrib><creatorcontrib>ANIKUMAR G. NAIR</creatorcontrib><creatorcontrib>LING TONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SOBHANA BABU BOGA</au><au>HUBERT B. JOSIEN</au><au>ABBAS M. WALJI</au><au>ELISABETTA BIANCHI</au><au>DANILA BRANCA</au><au>HAROLD B. WOOD</au><au>FA-XIANG DING</au><au>SOOKHEE NICOLE HA</au><au>CHENGWEI WU</au><au>YUSHENG XIONG</au><au>JIAN LIU</au><au>ANGELA DAWN KEREKES</au><au>THOMAS JOSEPH TUCKER</au><au>ANIKUMAR G. NAIR</au><au>LING TONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPUESTOS ANTAGONISTAS DE PCSK9</title><date>2021-05-28</date><risdate>2021</risdate><abstract>Se divulgan compuestos de Fórmula I, o una sal de los mismos: donde A, B, D, X, R1, R2 y R8 son como se definen en el presente documento, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales, y métodos para tratar enfermedades cardiovasculares y afecciones relacionadas con la actividad de PCSK9, ej., aterosclerosis, hipercolesterolemia, cardiopatía coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_NI202000101A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | COMPUESTOS ANTAGONISTAS DE PCSK9 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T19%3A24%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SOBHANA%20BABU%20BOGA&rft.date=2021-05-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENI202000101A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |